# Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

> **NCT05766371** · PHASE2 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 48 (estimated)

## Conditions studied

- Castrate Resistant Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer
- Prostate Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** 177Lu-PSMA-617

## Key facts

- **NCT ID:** NCT05766371
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-15
- **Primary completion:** 2027-05-31
- **Final completion:** 2031-05-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05766371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05766371, "Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05766371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*